CD4 and neoplasm: Although myeloid cells are assumed to be the main target of agonistic CD40 antibodies,59 we cannot exclude the possibility that agonistic CD40 boosts priming of CD8+ and CD4+ T cells in the tumor-draining lymph node.60 61 Alternatively, agonistic CD40 may induce tumoricidal tumor-infiltrating monocytes that deplete tumor stroma, resulting in tumor regression in a T cell–independent manner.62 In terms of our data, increased inflammation, induced independently of moDCs, may affect the differentiation of monocytes into moDCs.